Ionis Pharmaceuticals

News

GSK plans phase 3 for hepatitis B drug bepirovirsen, despite...

GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undete

News

FDA delays decision on Biogen's ALS hope tofersen

The FDA is planning to take an additional three months to review Biogen's experimental therapy for amyotrophic lateral sclerosis (ALS), setting back its decision date from January to April.

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AZ and Ionis' PCSK9 cholesterol drug will not move to phase ...

AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis into a phase 3 programme, removing a competitor to Novartis' rival therapy Leqvio.

News

Merck chases Bayer/Ionis with fast track for Factor XI drug

The FDA has given a novel anticoagulant from Merck & Co a fast-track designation as a treatment for people with end-stage renal disease (ESRD) who need dialysis, firing a warning short

News

Ionis antithrombotic with reduced bleed risk clears phase 2b...

Patients with end-stage renal disease (ESRD) who are on dialysis often need to be treated with anticoagulants to prevent blood clots, but as a result, can experience bleeding side effects.

News